Symmetric on Total Knee Arthroplasty (TKA)

Inclusion Criteria

• Patient is ≥ 18 years and 40 kg/m2;
• Patient is not able to walk independently (inability to walk at least 10 consecutive meters without a walking aid);
• Patient has had a surgical intervention during the past 30 days for treatment of painful joint or its underlying etiology;
• Patient has had previous open surgeries on the affected joint other than arthroscopy;
• Patient has active infectious collagen diseases (i.e. scleroderma) or any other condition that would interfere with wound healing;
• Patient is allergic to poly (p-dioxanone), triclosan (IRGACARE®* MP) or D&C Violet No. 2;
• Patient has diabetes with poor control, defined as fasting plasma glucose (FPG) ≥ 10.0 mmol/L;
• Patient has a history of immunosuppressive drug use, including steroids, within the last 6 months;
• Patient has undergone chemotherapy or radiation within the last 6 months prior to study enrollment or is scheduled to do so during the study period;
• Patient has known personal or family history of keloid formation or hypertrophy;
• Patient has other dermatologic conditions known to impair wound healing;
• Patient is participating in any other investigational drug (within 30 days or 5 half-lives of an investigational drug) or device study;
• Patient has any physical or psychological condition which would impair study participation; and
• Patient is judged unsuitable for study participation by the investigator for any other reason.